Hemodynamic responses and long-term follow-up results in patients using chronic beta 1-selective and nonselective beta-blockers during dobutamine stress echocardiography

Coronary Artery Disease

Volumn 17, Issue 5, 2006, Pages 447-453

  Feringa, Harm H H ^a   Bax, Jeroen J ^b   Elhendy, Abdou ^c   Van Domburg, Ron T ^a   Schouten, Olaf ^a   Krenning, Boudewijn ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

blockers; Blood pressure; Cardiac events; Dobutamine stress echocardiography; Heart rate; Prognostic value

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE FREE SURVIVAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART HEMODYNAMICS; HEART INFARCTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; BLOOD CIRCULATION; BLOOD PRESSURE; ECHOCARDIOGRAPHY, STRESS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; OBSERVATION; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA-1; TIME FACTORS;

EID: 33748136367     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200608000-00008     Document Type: Article

References (25)

1. Marwick TH. Stress echocardiography. Heart 2003; 89:113-118.
2. Poldermans D, Fioretti PM, Boersma E, Bax JJ, Thomson IR, Roelandt JR, et al. Long-term prognostic value of dobutamine-atropine stress echocardiography in 1737 patients with known or suspected coronary artery disease: a single-center experience. Circulation 1999; 99:757-762.
3. Leier CV, Unverferth DV. Drugs five years later. Dobutamine. Ann Intern Med 1983; 99:490-496.
4. Haeusler G. Pharmacology of β-blockers: classical aspects and recent developments. J Cardiovasc Pharmacol 1990; 16:S1-S9.
5. Prichard BN, Owens CW. Mode of action of β-adrenergic blocking drugs in hypertension. Clin Physiol Biochem 1990; 8:1-10.
6. Reiter MJ. Cardiovascular drug class specificity: β-blockers. Prog Cardiovasc Dis 2004; 47:11-33.
7. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Task force on beta-blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25:1341-1362.
8. Foody JM, Farrell MH, Krumholz HM. β-Blocker therapy in heart failure: scientific review. JAMA 2002; 287:883-889.
9. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
10. Williams EM, Hassan MO, Floras JS, Sleight P, Jones JV. Adaptation of hypertensives to treatment with β1-selective and non-selective β-blockers. Absence of correlation between bradycardia and blood pressure control, and reduction in slope of the QT/RR relation. Br Heart J 1980; 44:473-487.
11. Maack C, Elter T, Nickenig G, LaRosee K, Crivaro M, Stablein A, et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol 2001; 38:939-946.
12. Bollano E, Tang MS, Hjalmarson A, Waagstein F, Andersson B. Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart 2003; 89:621-624.
13. McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol 1992; 70:41-46.
14. Armstrong WF, Pellikka PA, Ryan T, Crouse L, Zoghbi WA. Stress echocardiography: recommendations for performance and interpretation of stress echocardiography. Stress Echocardiography Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 1998; 11:97-104.
15. Edwards WD, Tajik AJ, Seward JB. Standardized nomenclature and anatomic basis for regional tomographic analysis of the heart. Mayo Clin Proc 1981; 56:479-497.
16. Bourdillon PD, Broderick TM, Sawada SG, Armstrong WF, Ryan T, Dillon JC, et al. Regional wall motion index for infarct and noninfarct regions after reperfusion in acute myocardial infarction: comparison with global wall motion index. J Am Soc Echocardiogr 1989; 2:398-407.
17. Clark BJ. Beta-adrenoceptor-blocking agents: are pharmacologic differences relevant? Am Heart J 1982; 104:334-346.
18. Newton GE, Azevedo ER, Parker JD. Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study. Circulation 1999; 99:2402-2407.
19. Kindermann M, Maack C, Schaller S, Finkler N, Schmidt KI, Laer S, et al. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004;109:3182-3190.
20. Metra M, Nodari S, D'aloia A, Muneretto C, Robertson AD, Bristow MR, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomised comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:1248-1258.
21. Sicari R, Cortigiani L, Bigi R, Landi P, Raciti M, Picano E. Echo-Persantine International Cooperative (EPIC) Study Group; Echo-Dobutamine International Cooperative (EDIC) Study Group. Prognostic value of pharmacological stress cardiography is affected by concomitant antiischemic therapy at the time of testing. Circ 2004; 109:2428-2431.
22. Fioretti PM, Poldermans D, Salustri A, Forster T, Bellotti P, Boersma E, et al. Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers. Eur Heart J 1994; 15:355-360.
23. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol 1987;59:26F-32F.
24. Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293:416-418.
25. Ling LH, Pellikka PA, Mahoney DW, Oh JK, McCully RB, Roger VL, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996;28:551-557.